NASDAQ
28.01.25
21:59 Uhr
1,995 US-Dollar
-0,030
-1,48 %
-1,48 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYC | 71 | GlobeNewswire (Europe) | - PDUFA date of March 27, 2025 for CARDAMYST (etripamil) nasal spray for Paroxysmal Supraventricular Tachycardia (PSVT) - Commercial capabilities build out in process, with proposed launch in PSVT... ► Artikel lesen | |
| 07.01. | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 75 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards... ► Artikel lesen | |
| 12.11.24 | Milestone Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 12.11.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 171 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today reported financial results for the third quarter ended September 30, 2024 and... ► Artikel lesen | |
| 12.11.24 | Milestone Pharmaceuticals Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.10.24 | Milestone Pharmaceuticals maintains Buy rating from TD Cowen | 4 | Investing.com | ||
| MILESTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 14.10.24 | Wainwright maintains Buy rating on Milestone Pharma stock | 1 | Investing.com | ||
| 06.09.24 | Milestone Pharmaceuticals Inc.: Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China | 140 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 04.09.24 | Milestone Pharmaceuticals welcomes new board member Joseph Papa | 1 | Investing.com | ||
| 04.09.24 | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 04.09.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.08.24 | Milestone Pharmaceuticals GAAP EPS of -$0.14 | 1 | Seeking Alpha | ||
| 08.08.24 | Milestone Pharmaceuticals Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 118 | GlobeNewswire (Europe) | - NDA for CARDAMYST in PSVT accepted by FDA in 2Q 2024; PDUFA in March 2025 - Cash of $83.3 million as of June 30, 2024 expected to fund operations into 2026 - Stuart Duty and Andrew Saik Appointed... ► Artikel lesen | |
| 08.08.24 | Milestone Pharmaceuticals Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.05.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST | 261 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., May 29, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 13.05.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update | 200 | GlobeNewswire (Europe) | - NDA for etripamil in PSVT resubmitted in 1Q 2024- Cash resources as of March 31, 2024 expected to fund operations into 2026- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR... ► Artikel lesen | |
| 08.04.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting | 173 | GlobeNewswire (Europe) | MONTREAL and CHARLOTTE, N.C., April 08, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative... ► Artikel lesen | |
| 21.03.24 | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update | 250 | GlobeNewswire (Europe) | - On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2 Meeting... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 21,495 | +0,23 % | Nach 20-Jahres-Tief: Bayer: Aktie zweistellig im Plus seit Jahresbeginn - ist das der Turnaround? | © Foto: Juan Vega - EUROPA PRESSBayers Pharmasparte kämpft mit Umsatzrückgängen, doch Analysten sehen ab 2027 Wachstumspotenzial. Neue Medikamente und Strategien sollen die Patentklippe von Xarelto... ► Artikel lesen | |
| PFIZER | 25,715 | +0,31 % | Dividendenbekanntmachungen (24.01.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACERINOX SA ES0132105018 - EUR ALBERTSONS COMPANIES INC US0130911037 0,15 USD 0,144 EUR AUTO TRADER GROUP PLC GB00BVYVFW23 0,035... ► Artikel lesen | |
| GILEAD SCIENCES | 89,96 | -1,04 % | Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years | ||
| MERCK & CO | 93,50 | +0,11 % | MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag | ||
| VERTEX PHARMACEUTICALS | 422,00 | -0,28 % | Vertex Pharmaceuticals Incorporated: Vertex to Announce Fourth Quarter and Full Year 2024 Financial Results on February 10 | Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 7,980 | +4,29 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients... ► Artikel lesen | |
| ASSEMBLY BIOSCIENCES | 13,550 | +1,12 % | Assembly Biosciences, Inc.: Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B | - ABI-4334 was well-tolerated with a favorable safety profile and half-life supporting once-daily oral dosing observed - - In the first 150 mg dose cohort, ABI-4334 showed strong antiviral activity... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 7,500 | -0,53 % | Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update | BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported... ► Artikel lesen | |
| ROCKET LAB USA | 27,800 | -1,07 % | Raumfahrt: Im SpaceRace 2.0 geben die USA unter Präsident Trump mächtig Gas | ||
| NEWRON PHARMACEUTICALS | 9,880 | +1,86 % | Community-Rückblick: wO-User zu Newron Pharma nach Südkorea Deal: "2028 ist die Firma Geschichte..." | © Foto: ChatGPTDie Diskussion um Newron Pharma flammte erneut auf, nachdem die italienische Biotechfirma am 09.01. die Kooperation mit "Myung In Pharm", zwecks Vertrieb des Hoffnungsmittels Evenamide... ► Artikel lesen | |
| OPKO HEALTH | 1,464 | +4,12 % | OPKO Health, Inc.: ModeX Therapeutics Secures $35 Million BARDA Supplement to Develop COVID Multispecific Antibodies and $16 Million to Initiate Influenza Program | Brings total awards from BARDA to $110 million for development of broad SARS-CoV-2 and Influenza multispecifics, with potential funding of up to $205 million if all options are executedDevelopment... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 110,00 | +3,77 % | ROUNDUP: Ligand Pharmaceuticals Boosts FY24 Outlook | WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Thursday, biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND) raised its core adjusted earnings and... ► Artikel lesen | |
| ALTIMMUNE | 6,661 | -0,13 % | Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | ||
| JAZZ PHARMACEUTICALS | 119,05 | +0,29 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference | DUBLIN, Dec. 17, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will webcast its corporate presentation at the 43rd Annual J.P. Morgan Healthcare... ► Artikel lesen | |
| ROYALTY PHARMA | 30,530 | +0,96 % | Why Is Andreas Halvorsen Bullish On Royalty Pharma plc (RPRX) Now? |
MILESTONE PHARMACEUTICALS INC gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von -0,030 (-1,48 %) liegt der Kurs bei 1,995 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MILESTONE PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
